Kenneth Bender, PharmD, MA

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

CDC attributes a 15% increase in deaths from antimicrobial-resistant infections in 2020 to impacts of COVID-19 on health and healthcare.

Work group from infectious disease associations proposes prioritizing 6 areas of research to improve efficacy and precision of antibiotic therapy

Investigational vaccine demonstrates efficacy against respiratory syncytial virus in trial with adults inoculated with active RSV.

Algorithm offers guidance on clinically managing pregnant individuals exposed to monkeypox and on treating the virus during pregnancy.

Carbapenem-resistant enterobacterales in Saudi Arabia were genotyped and the course of illness characterized to help inform treatment and prevention.

At separate press conferences, the CDC and WHO indicate that containing monkeypox will depend on testing, tracing, and currently available vaccines.

The first report from WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) concedes SARS-CoV-2 source remains a mystery.

Rebound in COVID-19 symptoms, retesting positive for SARS-CoV-2, and recurring infectivity after Paxlovid treatment mars "test and treat."

New vaccine for COVID-19 employing receptor-binding domain-dimer-based platform achieves 87.6% efficacy against severe to critical illness.

Community transmission of monkeypox outside traditional endemic regions of the virus prompts calls for increased vigilance.

Study links inappropriate, off-guideline antibiotics to increased, avoidable allergic and adverse events in children.

Active immunization of pregnant women with investigational vaccine protected infants from RSV from birth through at least 6 months.

Historically low incidence of dengue in southeast Asia and Latin America linked to COVID-19 restrictions suggests potential future interventions.

Correlating immune response to COVID-19 vaccination in persons with HIV to their CD4 T-cell count could inform optimal vaccine strategy.

Investigators consider the low rate of vaccination in the rapidly increasing migrant populations in Europe, and call for improved strategies.

Selecting initial antibiotic for ventilator-associated pneumonia from Gram staining and resistance records could reduce broad spectrum agents.

Adding v-safe active monitoring to VAERS passive reporting produced "most comprehensive" program, and affirmed COVID-19 vaccine safety.

Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.

Both noncarbapenem β-lactams and carbapenems produced good outcomes in UTI from β-lactamase-producing Enterobacterales.

First-in-class triaminopyrimidine demonstrates antimalarial efficacy in first-in-human test of dosing, kinetics, and clearing parasite in infected volunteers.

Study with Medicare beneficiaries found those at highest risk of severe COVID-19 among least likely to receive monoclonal antibody treatment.

Investigators finding high risk for cardiovascular complications post-acute COVID-19 urge increased monitoring and preparedness.

Final analysis of phase 3, placebo-controlled trial confirms efficacy and safety of single-dose adenoviral vector vaccine against COVID-19.

Infection-acquired immunity to SARS-CoV-2 remains higher for longer when followed by vaccination.

A booster vaccination increases protection against COVID-19 whether homologous or heterologous with the primary vaccine.

The Centers for Disease Control and Prevention (CDC) compared 2-dose mRNA vaccination to third dose booster and to unvaccinated, against both Omicron and Delta variants of SARS-CoV-2.

With fewer monoclonal antibody treatments effective against the Omicron variant, the National Institutes of Health (NIH) now recommends direct-acting antivirals.

Casirivimab/imdevimab protected uninfected contacts from COVID-19 and reduced symptomatic infections in trials before Omicron emerged.

Study finds high false positive results with one batch of a rapid antigen test for SARS-CoV-2 but "very low" overall false positive rate.